Broker recommendations for Jounce Therapeutics
The Jounce Therapeutics, Inc. stock is rated at 1.642857 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Thursday 17 September, 2020 by a total of 7 brokers. This means that the consensus of the 7 different brokers is leaning toward to moderate buy/hold.
1 (14.29%) Underweight
0 (0%) Hold
2 (28.57%) Overweight
1 (14.29%) Buy
Price target by analysts
The 5 latest analyst estimates, per Thursday 17 September, 2020, show the following high, low and average price targets.
Target Average: 14.3 USD
Target High: 28 USD
Target Low: 5.5 USD
The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO
Wednesday, 16 September 2020, 14:00:28
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than doubled on its Wall Street debut) Repare Therapeutics Inc (NASDAQ: RPTX ) Revance Therapeutics Inc (NASDAQ: RVNC ) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) Histogen Inc (NASDAQ: HSTO ) PainReform Ltd (NASDAQ: PRFX ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) SILENCE THERAPE/S ADR (NASDAQ: SLN ) Stocks In Focus Roche Gets Label Expansion For Cancer Screening Test Roche Holdings AG Basel (OTC: RHHBY ) announced FDA approval for the expanded use of CINtec PLUS Cytology, its first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus.
Jounce inks license deal with Gilead valued up to $805M (NASDAQ:JNCE)
Tuesday, 1 September 2020, 14:47:35
Jounce Therapeutics (NASDAQ:JNCE) enters into an agreement with Gilead Sciences (NASDAQ:GILD) under which the latter will have exclusive global rights to p
— Seeking Alpha
Jounce Therapeutics Reports Second Quarter 2020 Financial Results
Friday, 7 August 2020, 08:30:00
– Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 – – On track to initiate Phase 2 SELECT …
Jounce Therapeutics Reports First Quarter 2020 Financial Results
Wednesday, 6 May 2020, 12:30:00
– Updating guidance on EMERGE and SELECT Phase 2 trials due to COVID-19 – – Announcing CCR8 as JTX-1811 target; new preclinical data to be presented…
What’s in Store for Jounce (JNCE) This Earnings Season?
Thursday, 20 February 2020, 16:31:00
Investors will look forward to pipeline updates when clinical-stage immunotherapy company, Jounce (JNCE), reports Q4 results.
— Zacks Investment Research